Large-scale genomic analysis of cfDNA from patients with advanced EGFRM+ NSCLC showed that specific genetic co-alterations in other cancer drivers (CDK6, CCNE1, CTNNB1, AR, MYC, BRCA1) may co-occur with T790M in advanced NSCLC, suggesting a collaborative functional role for these co-altered genes in driving EGFR-TKI resistance together with the T790M mutant [12]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.